A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder

• Status: Completed
• Trial end date: 2008-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This Phase IV, randomized, parallel-group study is designed to evaluate the cataractogenic potential of quetiapine fumarate (SEROQUEL) compared with that of a putative non-cataractogenic antipsychotic medication risperidone (RISPERDAL). This study is being conducted to fulfill the SEROQUEL Phase IV commitment regarding evaluation of cataractogenic potential.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Quetiapine Fumarate; Risperidone

Criteria

Inclusion Criteria:

• Men and women age 18 to 65

• Both Eyes present with lenses intact (no previous cataract extractions)

• Stable place of residency

Exclusion Criteria:

• History of corneal surgery

• Legal blindness (defined as best corrected visual acuity of 20/200 or worse in one or both eyes

• Previous participation in this study